The changing landscape for COX-2 inhibitors: a summary of recent events
Mamdani M. Healthc Q. 2005; 8(2):24-6.
Publications
Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000
Lee DS, Mamdani MM, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV. Am J Med. 2004; 116(9):581-9.
Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach
Laupacis A, Paterson JM, Mamdani M, Rostom A, Anderson GM. CMAJ. 2003; 169(11):1167-70.
Drug policy: making effective drugs available without bankrupting the healthcare system
Laupacis A, Anderson G, O'Brien B. Healthc Pap. 2002; 3(1):12-30.
Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?
Laupacis A. CMAJ. 2002; 166(1):44-7.
Adverse effects of observational studies when examining adverse outcomes of drugs: case-control studies with low prevalence of exposure
Austin PC, Mamdani M, Williams JI. Drug Saf. 2002; 25(9):677-87.
Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials
Parker AB, Naylor CD. Am Heart J. 2000; 139(6):952-61.